newsWill Novartis provide new oral option for chronic hives?9 August 2023 | By Catherine Eckford (European Pharmaceutical Review)If approved, Novartis’ remibrutinib has potential to be the first of a new class of chronic spontaneous urticaria (CSU) treatment in a decade.